AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pyxis Oncology: HC Wainwright Raises PT to $5, Reiterates Buy Rating
ByAinvest
Monday, May 19, 2025 7:01 am ET1min read
Pyxis Oncology: HC Wainwright Raises PT to $5, Reiterates Buy Rating
Pyxis Oncology, Inc. (Nasdaq: PYXS) has received a positive analyst upgrade from HC Wainwright, which has raised its price target to $5 per share. The investment bank reiterated its "Buy" rating on the biopharmaceutical company [1].The upgrade comes as Pyxis Oncology's CEO, Lara S. Sullivan, M.D., is scheduled to participate in fireside chats and investor meetings at the RBC Capital Markets Global Healthcare Conference on May 21 and the Jefferies Global Healthcare Conference on June 5 [2]. These events are expected to provide investors with insights into the company's pipeline of advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
Pyxis Oncology's lead candidate, micvotabart pelidotin (MICVO), is currently in Phase 1 clinical studies for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) [2]. Additionally, the company has initiated a Phase 1/2 combination study of MICVO with Merck's KEYTRUDA® (pembrolizumab) for advanced solid tumors [2]. These developments highlight Pyxis Oncology's commitment to addressing tough-to-treat cancers and its potential for strategic partnerships or funding opportunities.
The positive analyst upgrade comes amid recent insider trading activity, with insiders making purchases and institutional investors adding shares to their portfolios [3]. This activity underscores the growing interest in Pyxis Oncology's stock and its potential for growth.
References:
[1] https://www.nasdaq.com/articles/pyxis-oncology-inc-ceo-lara-s-sullivan-participate-upcoming-investor-conferences
[2] https://www.nasdaq.com/articles/pyxis-oncology-inc-ceo-lara-s-sullivan-participate-upcoming-investor-conferences
[3] https://www.nasdaq.com/articles/pyxis-oncology-inc-ceo-lara-s-sullivan-participate-upcoming-investor-conferences
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet